Farmakoterapie po srdecním infarktu
[Pharmacotherapy following myocardial infarction]
Language Czech Country Czech Republic Media print
Document type English Abstract, Journal Article, Review
PubMed
22165705
- MeSH
- Adrenergic beta-Antagonists therapeutic use MeSH
- Myocardial Infarction complications drug therapy MeSH
- Angiotensin-Converting Enzyme Inhibitors therapeutic use MeSH
- Platelet Aggregation Inhibitors therapeutic use MeSH
- Humans MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- English Abstract MeSH
- Journal Article MeSH
- Review MeSH
- Names of Substances
- Adrenergic beta-Antagonists MeSH
- Angiotensin-Converting Enzyme Inhibitors MeSH
- Platelet Aggregation Inhibitors MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors MeSH
Early reperfusion is the treatment of choice for acute coronary syndrome. In the Czech Republic, reperfusion therapy is well accessible thanks to the network of 22 catheterization centres. Every year, 28,000 patients are treated using this technique. Successful reperfusion should be followed by life style changes--smoking cessation, maintenance of appropriate body weight etc. These steps than has to be accompanied by effective pharmacotherapy to prevent remodelling of the left ventricle, re-stenosis of the coronary artery, re-thrombosis and arrhythmias. Four drug groups provide the desired effects--renin-angiotensin-aldosterone system blockers, beta-blockers, antiplatelet agents and statins.